Farmaindustria collaborates with the Patients' Organization Platform on responsible use of medicines

14 March 2016

Spanish pharma trade group Farmaindustria stated last week that working together in fostering the responsible use of medicines and the transparency of relations between the patients’ collective and the pharmaceutical sector are two of the main objectives of the collaboration agreement it has signed with the Patients’ Organizations Platform.

One of the foundations of the agreement will be the compliance and dissemination of the Code of Practice for the Pharmaceutical Industry and, more specifically, the regulation of the relations with patients’ organizations.

As stated in the agreement, Farmaindustria welcomes the patients’ organizations initiatives in Spain (fostered by the 26 members of the Platform), as well as the representative role of patients’ organizations which is carried out in a democratic and independent manner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK